Herceptin has been one of the most remarkable breakthroughs in treating breast cancer — but it can cause cardiac issues. The breast cancer drug Herceptin, also called trastuzumab, has been one ...

FeDeriCa is an international, multi-center, two-arm, randomized, open-label, Phase III study evaluating the pharmacokinetics, efficacy and safety of SC injection of the FDC of Perjeta and Herceptin in ...

First targeted medicine shown to improve overall survival in HER2-positive stomach and gastroesophageal junction cancers Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the U.S. Food and Drug ...

When you or a loved one has breast cancer, your doctor will figure out the best treatment options to offer you based on your particular tumor, your age, other conditions you have, and your wishes.

The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery. According to the FDA decision, announced yesterday, Herceptin may now be ...

Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive ...

Two recent studies offer hope of enhancing both the effectiveness and safety of Herceptin, the drug that helped introduce the era of targeted therapy. Two studies presented Saturday offer hope of ...

Washington, D.C. - Breast cancer patients with HER2-positive tumors who don't respond to Herceptin (trastuzumab) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K ...

Sometimes less may be better when it comes to treatment for breast cancer. A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six ...